Trial Profile
A Study to Investigate the Excretion Balance of SB-681323 in Healthy Male Volunteers [Type 3C]
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Neuropathic pain; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors GSK
- 11 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2007 New trial record.